Microwave ablation plus chemotherapy significantly improves progression-free survival in advanced NSCLC without increasing toxicity compared to chemotherapy alone. The combination treatment leverages ...
Biodexa Pharmaceuticals PLC (BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces an update ...
MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced topline results from the Phase III clinical trial, HARMONi, the first global Phase ...
The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no significant overall survival benefit. The study was a double-blind, multicenter ...
A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...
Gedatolisib, Faslodex, and Ibrance combination significantly improved progression-free survival in advanced breast cancer patients, reducing disease progression risk by 76%. The triplet regimen ...
INB-200 shows significantly improved progression-free survival in glioblastoma patients, with favorable safety profile and no serious toxicities reported. Repeated doses of INB-200 demonstrated an ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback